{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:30:47Z","timestamp":1776609047104,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.coph.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T01:19:21Z","timestamp":1494033561000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Norberto","family":"Perico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3446","authenticated-orcid":false,"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2017.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2011.368","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases","volume":"80","author":"Couser","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.coph.2017.03.006_bib0010","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0015","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1681\/ASN.2014101017","article-title":"Maintenance dialysis throughout the world in years 1990 and 2010","volume":"26","author":"Thomas","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0020","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/S2214-109X(16)00071-1","article-title":"Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study","volume":"4","author":"Ene-Iordache","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.coph.2017.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.mnh.0000222691.53970.83","article-title":"Progression of chronic kidney disease: insights from animal models","volume":"15","author":"Zoja","year":"2006","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.coph.2017.03.006_bib0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.coph.2017.03.006_bib0040","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0045","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0050","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","article-title":"Progression, remission, regression of chronic renal diseases","volume":"357","author":"Ruggenenti","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0055","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1681\/ASN.V105997","article-title":"In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia","volume":"10","author":"Ruggenenti","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0060","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/sj.ki.5000060","article-title":"ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease","volume":"69","author":"Remuzzi","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.coph.2017.03.006_bib0065","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1681\/ASN.2014100971","article-title":"Regression of renal disease by angiotensin II antagonism is caused by regeneration of kidney vasculature","volume":"27","author":"Remuzzi","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0075","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0080","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2017.03.006_bib0085","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1681\/ASN.V541139","article-title":"Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started","volume":"5","author":"Perico","year":"1994","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0095","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0100","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1681\/ASN.2012030252","article-title":"Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/dom.12583","article-title":"Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes","volume":"18","author":"Schievink","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.coph.2017.03.006_bib0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2008.03.008","article-title":"Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression","volume":"52","author":"Catapano","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.coph.2017.03.006_bib0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0120","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_sbref0125","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD","volume":"23","author":"Vegter","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_sbref0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S2213-8587(15)00094-7","article-title":"Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes","volume":"3","author":"Porrini","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.coph.2017.03.006_bib0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ndt\/gfu411","article-title":"Diabetic nephropathy: landmark clinical trials and tribulations","volume":"31","author":"Chan","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.coph.2017.03.006_bib0145","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0155","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2017.03.006_sbref0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0170","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium\u2013glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.coph.2017.03.006_sbref0175","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium\u2013glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"Skrtic","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.coph.2017.03.006_bib0180","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.coph.2017.03.006_bib0185","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.coph.2017.03.006_bib0190","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2017.03.006_bib0195","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2017.03.006_bib0200","doi-asserted-by":"crossref","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium\u2013glucose Co-transporter 2 inhibitor dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2017.03.006_sbref0205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.coph.2017.03.006_bib0210","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.03.006_bib0215","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.coph.2017.03.006_bib0220","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.coph.2017.03.006_bib0225","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.coph.2017.03.006_bib0230","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2337\/dc11-2189","article-title":"Glomerular hyperfiltration and renal disease progression in type 2 diabetes","volume":"35","author":"Ruggenenti","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2017.03.006_sbref0235","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0240","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.coph.2017.03.006_bib0250","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.coph.2017.03.006_bib0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.01.2720","article-title":"Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"126","author":"Nicolle","year":"2014","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.coph.2017.03.006_bib0260","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","article-title":"Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","volume":"30","author":"Nyirjesy","year":"2014","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T08:20:57Z","timestamp":1658996457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217300553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":52,"alternative-id":["S1471489217300553"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2017.03.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}